These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 26439700)
41. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139 [TBL] [Abstract][Full Text] [Related]
42. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin. Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386 [TBL] [Abstract][Full Text] [Related]
43. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Choi IS; Lee KW; Kim KH; Kim YJ; Kim JH; Lee JS Med Oncol; 2010 Sep; 27(3):992-7. PubMed ID: 20077040 [TBL] [Abstract][Full Text] [Related]
44. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716 [TBL] [Abstract][Full Text] [Related]
45. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161 [TBL] [Abstract][Full Text] [Related]
46. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256 [TBL] [Abstract][Full Text] [Related]
47. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356 [TBL] [Abstract][Full Text] [Related]
48. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T; Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560 [TBL] [Abstract][Full Text] [Related]
49. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Moehler M; Kanzler S; Geissler M; Raedle J; Ebert MP; Daum S; Flieger D; Seufferlein T; Galle PR; Hoehler T; Ann Oncol; 2010 Jan; 21(1):71-7. PubMed ID: 19605504 [TBL] [Abstract][Full Text] [Related]
50. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA; J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117 [TBL] [Abstract][Full Text] [Related]
51. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531 [TBL] [Abstract][Full Text] [Related]
52. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805 [TBL] [Abstract][Full Text] [Related]
53. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. Shitara K; Kadowaki S; Nishina T; Sakai D; Yoshikawa R; Piao Y; Ozeki A; Inoue K; Gritli I; Muro K Gastric Cancer; 2018 Jan; 21(1):106-113. PubMed ID: 28667466 [TBL] [Abstract][Full Text] [Related]
54. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501 [TBL] [Abstract][Full Text] [Related]
55. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Lenz HJ; Lee FC; Haller DG; Singh D; Benson AB; Strumberg D; Yanagihara R; Yao JC; Phan AT; Ajani JA Cancer; 2007 Jan; 109(1):33-40. PubMed ID: 17133415 [TBL] [Abstract][Full Text] [Related]
56. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). Koizumi W; Kim YH; Fujii M; Kim HK; Imamura H; Lee KH; Hara T; Chung HC; Satoh T; Cho JY; Hosaka H; Tsuji A; Takagane A; Inokuchi M; Tanabe K; Okuno T; Ogura M; Yoshida K; Takeuchi M; Nakajima T; J Cancer Res Clin Oncol; 2014 Feb; 140(2):319-28. PubMed ID: 24366758 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T; Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576 [TBL] [Abstract][Full Text] [Related]
58. Feasibility and efficacy of combination chemotherapy with S-1 and fractional Cisplatin for advanced gastric cancer. Takahashi T; Saikawa Y; Takaishi H; Takeuchi H; Wada N; Oyama T; Nakamura R; Kitagawa Y Anticancer Res; 2010 Sep; 30(9):3759-62. PubMed ID: 20944165 [TBL] [Abstract][Full Text] [Related]
59. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Shen L; Li J; Xu J; Pan H; Dai G; Qin S; Wang L; Wang J; Yang Z; Shu Y; Xu R; Chen L; Liu Y; Yu S; Bu L; Piao Y Gastric Cancer; 2015 Jan; 18(1):168-76. PubMed ID: 24557418 [TBL] [Abstract][Full Text] [Related]
60. Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer. Terazawa T; Iwasa S; Takashima A; Nishitani H; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y J Cancer Res Clin Oncol; 2013 Dec; 139(12):2111-6. PubMed ID: 24129809 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]